Legend Biotech Corp (LEGN) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows bearish technical indicators, declining financial performance, and mixed analyst sentiment. While the company's revenue growth is notable, its net income and EPS are significantly down, and competition concerns are weighing heavily on its future outlook. Given the lack of strong positive catalysts and no Intellectia Proprietary Trading Signals, it is better to hold off on investing in this stock for now.
The technical indicators for LEGN are bearish. The MACD is positive but contracting, RSI is neutral at 31.825, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its key support level of 17.682, with resistance at 20.83. This suggests limited upward momentum in the short term.

Revenue growth of 69.99% YoY in Q3 2025 demonstrates strong top-line performance. Analysts like Oppenheimer see the stock as undervalued and believe the risk/reward is skewed to the upside.
Declining net income (-68.33% YoY) and EPS (-67.65% YoY) indicate worsening profitability. Analyst downgrades, including a significant price target cut by Rothschild & Co Redburn, highlight concerns about competition and demand for the company's flagship product, Carvykti. The bearish sentiment in options trading further adds to the negative outlook.
In Q3 2025, revenue increased by 69.99% YoY to $272.33M. However, net income dropped by 68.33% YoY to -$39.69M, and EPS fell by 67.65% YoY to -0.11. Gross margin also declined to 57.66%, down 11.81% YoY, indicating profitability challenges.
Analyst sentiment is mixed but leaning negative. Recent downgrades from Rothschild & Co Redburn and TD Cowen highlight concerns over competition and demand for Carvykti. However, some analysts like Oppenheimer and Cantor Fitzgerald remain optimistic, citing undervaluation and differentiation of Carvykti. Price targets have been significantly lowered across the board, reflecting cautious sentiment.